Answers are grounded in this paper and cite their sources.
Merck & Co. recently reported one of the first mRNA display-derived clinical candidates in a bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Herein, we discuss the chemical and pharmacological challenges surmounted in bringing this compound to trials and the current outlook for mRNA display-based therapeutic development.
No takes yet. Share an insight, caveat, or question.
Iskandar et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: